AbCellera Biologics Inc (NASDAQ:ABCL) price on current trading day, rose 1.70% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $2.39.
A look at the stock’s price movement, the close in the last trading session was $2.35, moving within a range at $2.32 and $2.43. The beta value (5-Year monthly) was 0.452. Turning to its 52-week performance, $4.83 and $2.11 were the 52-week high and 52-week low respectively. Overall, ABCL moved -30.32% over the past month.
AbCellera Biologics Inc’s market cap currently stands at around $712.19 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-26.
Analysts have a consensus estimate of 7.12M for the company’s revenue for the quarter, with a low and high estimate of 4.6M and 17M respectively. The average forecast suggests down to a -28.43% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 26.29M, representing a -8.82% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ABCL is a 100% Sell. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
9 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 7 recommend ABCL as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ABCL’s current price about -6.61% and -18.52% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 40.22, while 7-day volatility ratio is 5.79% and 7.50% in the 30-day chart. Further, AbCellera Biologics Inc (ABCL) has a beta value of 0.47, and an average true range (ATR) of 0.19. Analysts have given the company’s stock an average 52-week price target of $5, forecast between a low of $5 and high of $5. Looking at the price targets, the low is -109.21% off current price level while to achieve the yearly target high, price needs to move -109.21%. Nonetheless, investors will most likely welcome a -109.21% jump to $5 which is the analysts’ median price.
If we refocus on AbCellera Biologics Inc (NASDAQ:ABCL), historical trading data shows that trading volumes averaged 4.21 over the past 10 days and 4.01 million over the past 3 months. The company’s latest data on shares outstanding shows there are 295.76 million shares.
The 24.97% of AbCellera Biologics Inc’s shares are in the hands of company insiders while institutional holders own 37.07% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 19.9 million on 2025-02-28, giving us a short ratio of 4.65. The data shows that as of 2025-02-28 short interest in AbCellera Biologics Inc (ABCL) stood at 864.9999999999999 of shares outstanding, with shares short rising to 18.43 million registered in 2025-01-31. Current price change has pushed the stock -18.43% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ABCL stock continues to rise going into the next quarter.
